Ivosidenib was initially approved in 2018 by the FDA for the treatment of acute myeloid leukemia (AML) with an IDH-1 mutation but showed great promise in a recent phase III clinical trial in CCA patients [7]. The gene discussed is IDH1; the disease is acute myeloid leukemia.